Dyadic International (DYAI) Competitors $0.79 0.00 (-0.62%) Closing price 04:00 PM EasternExtended Trading$0.79 +0.00 (+0.10%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYAI vs. IKT, SCLX, SKYE, TNYA, FATE, SAVA, ZNTL, HLVX, CRBP, and ADAGShould you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include Inhibikase Therapeutics (IKT), Scilex (SCLX), Skye Bioscience (SKYE), Tenaya Therapeutics (TNYA), Fate Therapeutics (FATE), Cassava Sciences (SAVA), Zentalis Pharmaceuticals (ZNTL), HilleVax (HLVX), Corbus Pharmaceuticals (CRBP), and Adagene (ADAG). These companies are all part of the "pharmaceutical products" industry. Dyadic International vs. Its Competitors Inhibikase Therapeutics Scilex Skye Bioscience Tenaya Therapeutics Fate Therapeutics Cassava Sciences Zentalis Pharmaceuticals HilleVax Corbus Pharmaceuticals Adagene Inhibikase Therapeutics (NYSE:IKT) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk. Which has better earnings and valuation, IKT or DYAI? Dyadic International has higher revenue and earnings than Inhibikase Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.64Dyadic International$3.49M8.19-$5.81M-$0.19-4.16 Is IKT or DYAI more profitable? Inhibikase Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -134.84%. Inhibikase Therapeutics' return on equity of -350.63% beat Dyadic International's return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -350.63% -201.82% Dyadic International -134.84%-355.39%-60.66% Do analysts recommend IKT or DYAI? Inhibikase Therapeutics presently has a consensus price target of $6.50, indicating a potential upside of 282.35%. Dyadic International has a consensus price target of $6.00, indicating a potential upside of 659.30%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts clearly believe Dyadic International is more favorable than Inhibikase Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in IKT or DYAI? 3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 7.3% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 29.5% of Dyadic International shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, IKT or DYAI? Inhibikase Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Does the media favor IKT or DYAI? In the previous week, Dyadic International had 2 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 5 mentions for Dyadic International and 3 mentions for Inhibikase Therapeutics. Dyadic International's average media sentiment score of 0.27 beat Inhibikase Therapeutics' score of -0.13 indicating that Dyadic International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyadic International 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryDyadic International beats Inhibikase Therapeutics on 10 of the 14 factors compared between the two stocks. Get Dyadic International News Delivered to You Automatically Sign up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYAI vs. The Competition Export to ExcelMetricDyadic InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.77M$3.06B$5.75B$9.64BDividend YieldN/A2.22%3.91%4.09%P/E Ratio-4.1620.6130.7825.12Price / Sales8.19360.20458.48157.26Price / CashN/A41.5625.2228.45Price / Book-79.029.509.365.94Net Income-$5.81M-$54.72M$3.26B$265.56M7 Day Performance-7.04%2.39%1.83%0.95%1 Month Performance-18.85%4.60%3.69%2.47%1 Year Performance-41.90%9.11%28.88%20.24% Dyadic International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYAIDyadic International3.3644 of 5 stars$0.79-0.6%$6.00+659.3%-39.8%$28.77M$3.49M-4.167Earnings ReportGap UpIKTInhibikase Therapeutics2.0339 of 5 stars$1.51+5.6%$6.50+330.5%+35.4%$112.26MN/A-0.576News CoverageGap UpSCLXScilex2.0939 of 5 stars$15.82+0.6%$455.00+2,776.1%-55.0%$109.28M$56.59M-0.5580Earnings ReportGap UpSKYESkye Bioscience1.8866 of 5 stars$3.51-0.3%$16.60+372.9%-27.3%$109.08MN/A-3.3111TNYATenaya Therapeutics2.8189 of 5 stars$0.68+1.8%$6.25+817.5%-56.4%$109.01MN/A-0.71110Gap UpFATEFate Therapeutics4.0585 of 5 stars$0.94+1.6%$3.83+309.7%-64.7%$105.60M$13.63M-0.63550Earnings ReportAnalyst UpgradeSAVACassava Sciences2.2802 of 5 stars$2.25+3.2%$2.00-11.1%-92.0%$105.31MN/A-1.5030Earnings ReportZNTLZentalis Pharmaceuticals1.993 of 5 stars$1.40-2.8%$8.20+485.7%-47.6%$103.88M$67.43M-0.62160News CoverageHLVXHilleVax1.5752 of 5 stars$2.06-0.5%$2.00-2.9%+15.1%$103.54MN/A-1.4420CRBPCorbus Pharmaceuticals4.1352 of 5 stars$8.67+2.8%$49.00+465.2%-82.7%$103.31MN/A-1.8240ADAGAdagene2.932 of 5 stars$2.29+5.5%$7.50+227.5%-21.6%$102.23M$100K0.00260Gap Up Related Companies and Tools Related Companies Inhibikase Therapeutics Alternatives Scilex Alternatives Skye Bioscience Alternatives Tenaya Therapeutics Alternatives Fate Therapeutics Alternatives Cassava Sciences Alternatives Zentalis Pharmaceuticals Alternatives HilleVax Alternatives Corbus Pharmaceuticals Alternatives Adagene Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYAI) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyadic International Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyadic International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access